Metabolic / Weight Loss · 5mg × 10 vials
it suppresses appetite harder than semaglutide, slows the stomach, improves how the body handles sugar, and the GIP arm tends to make people feel less nauseous at equivalent appetite-suppression levels.
Tirzepatide is a once-weekly 39-amino-acid injectable peptide that activates two incretin receptors simultaneously: GLP-1 (the "Ozempic pathway", appetite suppression + delayed gastric emptying + insulin secretion) and GIP (glucose-dependent insulinotropic polypeptide, which amplifies insulin response, blunts glucagon, and is thought to actively soften the nausea profile vs pure GLP-1s like semaglutide). The drug is built on a GIP backbone with a C20 fatty di-acid moiety that binds albumin and stretches the half-life to ~5 days for true once-weekly dosing. In plain language: it suppresses appetite harder than semaglutide, slows the stomach, improves how the body handles sugar, and the GIP arm tends to make people feel less nauseous at equivalent appetite-suppression levels. That dual-receptor hit is also why tirz typically outperforms sema in head-to-head reads - SURMOUNT-5 (2025) put tirz at 20.2% body weight loss vs sema at 13.7% over 72 weeks.
Typical dose ranges by experience level - educational reference. Message us and we tailor it to you.
This is the most common first GLP-1 for PP customers because the GIP arm makes the nausea curve materially gentler than semaglutide at equivalent appetite suppression. Sensitive users can start at 1.25 mg (half the label dose) and see real appetite reduction inside the first 1-2 injections. Reconstitute the 10 mg vial with 1 ml BAC = 10 mg/ml (minimal-volume default), so 2.5 mg = 0.25 ml = 25 IU on a U-100 syringe. Inject subQ into abdomen or outer thigh, rotate sites.
SURMOUNT-1 reported 19.5% mean weight loss at 10 mg and 20.9% at 15 mg over 72 weeks. SURMOUNT-2 in T2D pts showed A1C reductions of 2.04% (10 mg) and 2.30% (15 mg). Push to 15 mg only if 10-12.5 mg has stopped producing appetite suppression. The trial-set rapid 2.5 mg/month steps are too aggressive for many users; community standard is to hold any step 6-8 weeks if GI sides are still active.
Above 15 mg the risk-reward starts shifting - published SURMOUNT data caps at 15 mg, so any push past that is community-derived. Heart rate creep, gallbladder risk, and lean mass loss all scale with dose and rate of loss. After hitting target, taper to 5-10 mg/wk maintenance. SURMOUNT-4 withdrawal data is the hard lesson: placebo arm regained 14% body weight over 52 weeks after stopping tirz cold, so don't stop, taper. Customers plateauing at 15 mg are usually better served switching to retatrutide than pushing tirz past the label ceiling.
Straight talk - what people actually report, and what the studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
pivotal Phase 3, 2,539 pts, 20.9% body weight loss at 15 mg over 72 wk
Read study ↗PubMedSURMOUNT-1 long-term 176-week extension, NEJM 202419.7% sustained loss at 15 mg over 176 wk
Read study ↗PubMedFrias et al, SURPASS-2, NEJM 2021head-to-head vs semaglutide in T2D, 2.30% A1C reduction at 15 mg vs 1.86% sema
Read study ↗PubMedSURMOUNT-4 maintenance trial, JAMA 2024 (PMC10714284)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10714284/) - 14% weight regain in placebo arm after withdrawal, 25.3% total loss with continued tirz
Read study ↗PubMedRubino et al, GI tolerability pooled analysis SURMOUNT-1 to -4, DOM 2025pooled AE rates, discontinuation 1-10.5% by arm
Read study ↗PubMedSURMOUNT-5 head-to-head vs semaglutide, NEJM 202520.2% tirz vs 13.7% sema at 72 wk
Read study ↗Aggregated sentiment from public forums & socials - real-world reports, not individual endorsements.
Nausea: most-reported sensation, peaks weeks 2-8 after each dose step, manageable with low-fat meals 24-48 hr post-injection, smaller portions, ginger, and morning dosing. Community consensus: extending hold time at each step from 4 to 6-8 weeks cuts nausea reports significantly.
Sulfur burps / "eggy burps": 3-5% prevalence per clinical signal, but community reports it closer to 15-25% during the first weeks of treatment and after dose increases. Resolves once dose stabilizes.
- Divergence: clinical literature underreports sulfur burps; the community treats it as a near-universal early-titration symptom that nobody warns you about.
Fatigue / "tirz fog": more often reported in community than in trials. Many users describe a 2-3 week "blah" period at each new dose step.
- Divergence: RCTs don't break out fatigue as a top AE; community describes it as one of the more common reasons people delay titrating up.
Constipation: community reports 30%+ at higher doses, well above the 11-17% RCT signal. Magnesium citrate and fiber are the standard fixes.
Route: SubQ
Injection site: Abdomen (2 inches off the navel), outer thigh, or back of the upper arm. Rotate sites weekly to avoid lipohypertrophy.
Storage: Refrigerated (36-46F), good for 28-30 days after reconstitution. Dry/lyophilized vial frozen and away from light is stable 2+ years.
Notes: Inject same day each week to match the ~5 day half-life. Most users report morning injection on a low-fat day after dosing reduces nausea peak.